Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14(ARF) Tumor Suppressor Genes

The adenovirus mutant ONYX-015 is in phase III clinical trials as a novel antitumor therapy. Its apparent efficacy is thought to be due to its ability to replicate selectively in tumor cells defective in the signaling pathway for p53. Recent data have shown that p14(ARF), a positive regulator of p53...

Descripción completa

Detalles Bibliográficos

Publicado en:	J Virol
Autores principales:	Edwards, Sara J., Dix, Brett R., Myers, Colleen J., Dobson-Le, Deirdre, Huschtscha, Lily, Hibma, Merilyn, Royds, Janice, Braithwaite, Antony W.
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	American Society for Microbiology (ASM) 2002
Materias:	Replication
Acceso en línea:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC136704/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12438574/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/JVI.76.24.12483-12490.2002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!